Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ionis Pharmaceuticals (IONS) -- Ignore unavailable to you. Want to Upgrade?

To: Micawber who wrote (2533)	3/20/1999 3:42:00 PM
From: Art Bechhoefer	Respond to of 4676

To: All One need not rely solely on the existing approved product or on those nearing final testing. There is a consortium of research/teaching hospitals, for example, testing various drugs for brain cancer. Among these is one of the ISIS drugs. The results so far are promising. The early data is simply anecdotal and is not sufficient to show statistical significance. However, I think the important issue for investors is whether the technology is promising enough. By the time the tests VERIFY this, the stock will already have gone up. Another way to take advantage of some of the ISIS technology without as much risk as directly investing in ISIS is to buy shares in ZENECA, a large British drug firm that has a working alliance with ISIS and shares in the profits of whatever may eventually be developed. My own view, which is that of an investor with some background in biotech and related technologies, and with some familiarity with the research literature, is that the stock is a reasonable value at its present price, but ONLY for those willing to wait for possibly three or more years before it really takes off. The reason for buying it early is that you never know when some unexpected good news will send the share price out of sight. Art Bechhoefer